FHIR & Cancer Reporting: USCDI+ Updates for Better Care

Advancing Cancer Care Thru Data Standardization: The‍ Enhancing Oncology⁤ Model

The fight against cancer demands collaboration and, ‍increasingly, relies on the power of data. The Enhancing Oncology Model (EOM) ⁣ is a pivotal initiative⁣ designed to standardize essential cancer-related ⁢clinical data within electronic health records ⁢(EHRs). This ⁢standardization is key to improving how⁢ we share details, deliver care, and ultimately, improve outcomes‍ for cancer patients.

The Challenge of Cancer Data Interoperability

For too long, cancer data has been fragmented across different healthcare systems.⁣ this lack of interoperability hinders research,‍ complicates care coordination, and makes it difficult to track progress on a⁣ national scale. ⁢The EOM directly addresses this challenge.

USCDI+ Cancer: A Collaborative Approach

The⁢ USCDI+ Cancer team began by focusing on the EOM Use ⁢Case to demonstrate the feasibility of exchanging cancer data using established Fast Healthcare Interoperability Resources® (FHIR®) standards. This wasn’t a solo effort. ⁤

Numerous organizations⁢ joined forces, including:

ASTP
CMS (Centers for Medicare & Medicaid Services)
The HL7® minimal Clinical Oncology Data Elements⁣ (mCODE) group

Together, they rapidly developed a FHIR Implementation Guide to support⁢ the submission of clinical and sociodemographic data for EOM’s performance Period 1 (PP1). This guide prepared providers for the reporting submission deadline of October 31, 2024.

“High Tech” vs.”Low Tech”⁢ Reporting for PP1

For PP1, providers had two options for submitting the required data elements:

“Low Tech”: Traditional chart abstraction – a manual, time-consuming process.
“High Tech”: Automated submission via FHIR API -⁢ a streamlined, efficient approach.The results were encouraging.Several vendors successfully transmitted data on behalf of their EOM-enrolled providers ⁤to⁤ CMS using FHIR API, mCODE, and aligning with USCDI+ Cancer⁤ data elements. Early feedback suggests a growing trend toward ‍the “high tech” method as⁣ we move⁣ into Performance Period 2.

Why This Matters to You

what does‍ this mean ‍for you, whether you’re a healthcare provider, a patient, or a researcher?

For Providers: Streamlined reporting, reduced administrative burden, and the ability to participate in⁤ value-based care initiatives.
For⁤ Patients: More coordinated care, access to the latest research, and perhaps improved ⁢outcomes.
For Researchers: ⁢ Access to larger, more complete datasets to accelerate discoveries and improve cancer prevention ⁤and treatment.

The ⁣Power of Collaboration & Future Outlook

The success of the EOM’s initial ⁣phase underscores the vital importance of interagency and cross-sector collaboration. Addressing the complexities of data⁤ standards and interoperability requires a unified effort.

FHIR-based reporting for cancer data is a significant step toward a more connected and effective healthcare system. Continued partnerships and commitment ‍from all stakeholders are essential as⁤ we work to improve cancer care nationwide and⁢ deliver high-quality, patient-centered treatment for all.

Leave a Comment